ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin® SoftgelsPosted by On

SASKATOON, Saskatchewan–(BUSINESS WIRE)– #AdvancingtheScienceofWellbeing–ZYUS Life Sciences Corporation (“ZYUS” or the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company leading scientific research and global development of innovative cannabinoid-based pharmaceutical drug products, is pleased to announce receipt of the final clinical study report and positive results respecting its Phase 1, first-in-human (“FIH”) Clinical Trial for its lead drug product candidate, Trichomylin® softgels. About Trichomylin Softge

Source link


Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.